Monoclonal antibodies in sepsis and septic shock.
作者信息
Hinds C J
出版信息
BMJ. 1992 Jan 18;304(6820):132-3. doi: 10.1136/bmj.304.6820.132.
Abstract
摘要
相似文献
1
Monoclonal antibodies in sepsis and septic shock.脓毒症和感染性休克中的单克隆抗体。
BMJ. 1992 Jan 18;304(6820):132-3. doi: 10.1136/bmj.304.6820.132.
2
Human monoclonal antibodies in sepsis.脓毒症中的人单克隆抗体。
Neth J Med. 1992 Apr;40(3-4):215.
3
[Introduction of immunotherapeutic agents in clinical practice; current status concerning anti-endotoxin antibody HA-1A in the control of sepsis].[免疫治疗药物在临床实践中的应用介绍；抗内毒素抗体HA-1A在脓毒症控制中的现状]
Ned Tijdschr Geneeskd. 1993 Feb 13;137(7):334-6.
4
New treatments for septic shock.脓毒性休克的新疗法。
Postgrad Med. 1992 Feb 15;91(3):47-8.
5
Monoclonal therapy for bacteremia and sepsis.用于治疗菌血症和败血症的单克隆疗法。
West J Med. 1992 Aug;157(2):174.
6
Antiendotoxin therapy in sepsis.脓毒症的抗内毒素治疗
Crit Care Nurs Clin North Am. 1993 Jun;5(2):345-54.
7
Monoclonal antibody HA-1A for gram-negative shock.用于革兰氏阴性菌休克的单克隆抗体HA-1A
Lancet. 1991 Sep 14;338(8768):695-6. doi: 10.1016/0140-6736(91)91272-v.
8
Mechanism for monoclonal antibody mediated treatment of gram-negative shock.
Lancet. 1991 Jul 20;338(8760):186. doi: 10.1016/0140-6736(91)90174-n.
9
[Immunotherapy in sepsis syndrome].
Ned Tijdschr Geneeskd. 1992 May 30;136(22):1050-4.
10
Putting the cart before the horse: a cautious look at the role of IgM-enriched polyclonal immunoglobulin in sepsis therapy.
J Crit Care. 2005 Sep;20(3):249-50. doi: 10.1016/j.jcrc.2005.06.002.
引用本文的文献
1
The birth pangs of monoclonal antibody therapeutics: the failure and legacy of Centoxin.单克隆抗体治疗药物的诞生之痛：抑瘤素 M 的失败与遗产。
MAbs. 2012 May-Jun;4(3):403-12. doi: 10.4161/mabs.19909. Epub 2012 Apr 26.
2
Therapeutic applications of monoclonal antibodies.单克隆抗体的治疗应用。
Am J Med Sci. 2002 Jul;324(1):14-30. doi: 10.1097/00000441-200207000-00004.
3
Back to the future: antibody-based strategies for the treatment of infectious diseases.回到未来：基于抗体的传染病治疗策略。
Mol Biotechnol. 2002 Jul;21(3):225-39. doi: 10.1385/MB:21:3:225.
4
Treatment of sepsis with activated protein C.用活化蛋白C治疗脓毒症。
BMJ. 2001 Oct 20;323(7318):881-2. doi: 10.1136/bmj.323.7318.881.
5
Neutrophil-mediated tissue injury and its modulation.
Intensive Care Med. 1995 Mar;21(3):277-85. doi: 10.1007/BF01701489.
6
The cost of intensive care: a comparison on one unit between 1988 and 1991.重症监护的成本：1988年至1991年一个科室的比较
Intensive Care Med. 1994 Nov;20(8):542-9. doi: 10.1007/BF01705718.
7
Monoclonal antibodies in sepsis.脓毒症中的单克隆抗体
BMJ. 1992 Apr 18;304(6833):1054-5. doi: 10.1136/bmj.304.6833.1054-a.
8
Monoclonal antibodies in sepsis and septic shock.脓毒症和脓毒性休克中的单克隆抗体。
BMJ. 1992 Mar 7;304(6827):639-40. doi: 10.1136/bmj.304.6827.639-c.
9
Principles of antibody therapy.抗体治疗的原理。
BMJ. 1992 Dec 5;305(6866):1424-9. doi: 10.1136/bmj.305.6866.1424.
10
The pulmonary physician and critical care. 3. Pharmacotherapy in lung injury.肺科医生与重症监护。3. 肺损伤的药物治疗。
Thorax. 1992 Aug;47(8):651-6. doi: 10.1136/thx.47.8.651.
本文引用的文献
1
Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli.用人抗突变型大肠杆菌抗血清治疗革兰氏阴性菌血症和休克。
N Engl J Med. 1982 Nov 11;307(20):1225-30. doi: 10.1056/NEJM198211113072001.
2
Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies.用人源单克隆IgM抗体预防革兰氏阴性菌血症和内毒素血症。
Proc Natl Acad Sci U S A. 1985 Mar;82(6):1790-4. doi: 10.1073/pnas.82.6.1790.
3
Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia.抗恶病质素/肿瘤坏死因子单克隆抗体可预防致死性菌血症期间的感染性休克。
Nature. 1987;330(6149):662-4. doi: 10.1038/330662a0.
4
Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind, randomized trial.
J Infect Dis. 1988 Aug;158(2):312-9. doi: 10.1093/infdis/158.2.312.
5
Immunization with rough mutants of Salmonella minnesota: protective activity of IgM and IgG antibody to the R595 (Re chemotype) mutant.用明尼苏达沙门氏菌粗糙突变株进行免疫：针对R595（Re化学型）突变株的IgM和IgG抗体的保护活性。
J Infect Dis. 1988 Aug;158(2):291-300. doi: 10.1093/infdis/158.2.291.
6
Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid.通过抗内毒素核心糖脂抗体预防外科手术患者革兰氏阴性菌感染性休克及死亡。
Lancet. 1985 Jul 13;2(8446):59-63. doi: 10.1016/s0140-6736(85)90176-x.
7
Initial evaluation of a human immunoglobulin M monoclonal antibody (HA-1A) in humans.
J Biol Response Mod. 1990 Apr;9(2):178-84.
8
Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumor necrosis factor alpha and interleukin 6. Comparison of O side chain-specific antibodies with core LPS antibodies.抗脂多糖（LPS）抗体的保护效力与LPS诱导的肿瘤坏死因子α及白细胞介素6抑制之间的关联。O侧链特异性抗体与核心LPS抗体的比较。
J Exp Med. 1990 Mar 1;171(3):889-96. doi: 10.1084/jem.171.3.889.
9
Initial evaluation of human monoclonal anti-lipid A antibody (HA-1A) in patients with sepsis syndrome.人类单克隆抗脂质A抗体（HA-1A）在脓毒症综合征患者中的初步评估。
Crit Care Med. 1990 Dec;18(12):1311-5. doi: 10.1097/00003246-199012000-00001.
10
Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF alpha).
Circ Shock. 1990 Mar;30(3):279-92.
Zotero 插件